Compare TIRX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIRX | IMNN |
|---|---|---|
| Founded | 2010 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 12.5M |
| IPO Year | 2019 | 2000 |
| Metric | TIRX | IMNN |
|---|---|---|
| Price | $0.03 | $3.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 42.1M | 26.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.37 |
| 52 Week High | $3.45 | $9.32 |
| Indicator | TIRX | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 60.75 |
| Support Level | N/A | $3.53 |
| Resistance Level | $0.12 | $3.62 |
| Average True Range (ATR) | 0.02 | 0.21 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 5.85 | 92.45 |
Tian Ruixiang Holdings Ltd is an Insurance Brokerage firm. It distributes a wide range of insurance products, which are categorized into two groups; property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and other insurances, such as health insurance, life insurance, and miscellaneous insurances. It also generates a small amount of revenue from risk management services. The firm act on behalf of its customers seeking insurance coverage from insurance companies. It generates revenue from the provision of insurance brokerage services.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).